Results 161 to 170 of about 74,894 (279)

Complete Blood Count Profile in Steady State Sickle Cell Disease Patient: A Systematic Review and Meta‐Analysis

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims Sickle cell disease is a genetic disorder whose pathophysiology is primarily characterized by vasoocclusive crises and hemolytic crises. The stationary phase describes the interval between two vasoocclusive crises. The aim of this systematic review and meta‐analysis was to synthesize studies published over the past two ...
Josué Louokdom Simo, Romaric De Manfouo Tuono, Ingrid Worti Sulem Yong, Prisca Tipane Angandji, Maryline Seuko Njopwouo, Claude Tagny Tayou   +5 more
wiley   +1 more source

Is Micronucleus Assay a Suitable Biomarker for Evaluating the Cancer Risk in Professionals Exposed to Antineoplastic Drugs? A Systematic Review

Journal of Applied Toxicology, Volume 46, Issue 3, Page 733-753, March 2026.
ABSTRACT The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity.
Thiago Guedes Pinto, Lorrany da Silva Avanci, Gabriel Carvalhal de Aguiar, Daniel Vitor de Souza, Patricia Ramos Cury, Ana Claudia Muniz Renno, Daniel Araki Ribeiro   +6 more
wiley   +1 more source

Clinical methemoglobinemia secondary to administration of hydroxyurea at therapeutic doses in a dog

Journal of Veterinary Internal Medicine
Methemoglobinemia secondary to administration of hydroxyurea is only reported in veterinary medicine as a result of accidental ingestion of high doses, and once at therapeutic dose in human medicine.
Manon Rigot, Shane W. Bateman, Xiu Ting Yiew   +2 more
doaj   +1 more source

Hydroxyurea-induced melanonychia

JAAD Case Reports, 2023
Michael G. Buontempo, BS, Zaima S. Chaudhry, MD, Ruchi S. Raval, BS, Kelly Mourtzanakis, BS, Vignesh Ramachandran, MD, Jerry Shapiro, MD, Kristen Lo Sicco, MD   +6 more
openaire   +3 more sources

Liquid Hydroxyurea (Xromi) for Children With Sickle Cell Anemia: A New Solution Compounding Existing Problems

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
Alexandra Power‐Hays, Charles T. Quinn
wiley   +1 more source

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen, Jingtian Yu, Wuqiang Wen, Baishan Jiang   +3 more
wiley   +1 more source

Hydroxyurea

Journal of Biological Chemistry, 1967
Roger L.P. Adams, J.G. Lindsay
openaire   +1 more source

Assessment and Benchmarking of Model Informed Approaches in Drug Development for Hemoglobinopathies: A Review of Scientific Advices From January 2000 to December 2024

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Despite the fact that modeling and simulation are now recognized as promising innovative methodologies, their use in the context of development of drugs for sickle cell disease and Thalassemia has not yet been reviewed. Considering the challenges of conducting clinical trials for hemoglobinopathies, our work aims at exploring the current ...
Grace Shalom Govere, Jean‐Michel Dogné, Flora Musuamba   +2 more
wiley   +1 more source

Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open‐Label, Randomized Controlled Study

American Journal of Hematology, Volume 101, Issue 3, Page 628-632, March 2026.
Zhenbin Wei, Rongrong Liu, Lingling Shi, Qiaochuan Li, Lianjin Liu, Baoshi Zheng, Chunjie Qin, Hong Chen, Guyun Wang, Meiqing Wu, Gaohui Yang, Ruolin Li, Zhaoping Gan, Qi Zhou, Jing Fan, Xuemei Zhou, Yinghua Chen, Zhiyu Zeng, Zhongming Zhang, Yongrong Lai   +19 more
wiley   +1 more source

Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study

European Journal of Haematology, Volume 116, Issue 3, Page 302-310, March 2026.
ABSTRACT Since 2004, patients receiving imatinib with relapse in non‐marrow sites were given dasatinib to preserve control of leukemic marrow. Remissions in CNS and other organs began to be reported and are continuously observed to present. With resistance to one BCR::ABL1 tyrosine kinase inhibitor and sensitivity to a dual BCR::ABL1/SRC inhibitor ...
I. Cunningham, R. A. Fisher, J. Yang, Y. Guo, U. Bommhardt   +4 more
wiley   +1 more source